Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Immune Disorders

Imraldi sets pace on German price cuts

  • News

Executive Summary

Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.

Table

View full table

Topics

Tags:
Immune Disorders
Latest Headlines

Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds

Viatris Reveals Next Steps For Once-Monthly US Copaxone Rival After Rejection

Boehringer Allies With Quallent For Push On Adalimumab

Organon Reports Boosted Growth In Biosimilars Portfolio Revenue

See All
UsernamePublicRestriction

Register

GB001401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By